These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 18276045

  • 1. Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a.
    Turbyfill KR, Kaminski RW, Oaks EV.
    Vaccine; 2008 Mar 04; 26(10):1353-64. PubMed ID: 18276045
    [Abstract] [Full Text] [Related]

  • 2. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV, Turbyfill KR.
    Vaccine; 2006 Mar 20; 24(13):2290-301. PubMed ID: 16364513
    [Abstract] [Full Text] [Related]

  • 3. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex.
    Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW.
    mSphere; 2018 Mar 20; 3(2):. PubMed ID: 29600284
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
    Tribble D, Kaminski R, Cantrell J, Nelson M, Porter C, Baqar S, Williams C, Arora R, Saunders J, Ananthakrishnan M, Sanders J, Zaucha G, Turbyfill R, Oaks E.
    Vaccine; 2010 Aug 23; 28(37):6076-85. PubMed ID: 20619378
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
    Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.
    Vaccine; 2011 Sep 16; 29(40):7009-19. PubMed ID: 21787825
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH, Chang SY, Park SM, Jang H, Carbis R, Czerkinsky C, Uematsu S, Akira S, Kweon MN.
    Vaccine; 2007 Jun 15; 25(25):4828-36. PubMed ID: 17507120
    [Abstract] [Full Text] [Related]

  • 7. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.
    Turbyfill KR, Hartman AB, Oaks EV.
    Infect Immun; 2000 Dec 15; 68(12):6624-32. PubMed ID: 11083774
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL.
    Vaccine; 2006 May 01; 24(18):3735-45. PubMed ID: 16095766
    [Abstract] [Full Text] [Related]

  • 9. Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (InvaplexAR) vaccines.
    Turbyfill KR, Clarkson KA, Oaks EV, Zurawski DV, Vortherms AR, Kaminski RW.
    mSphere; 2023 Aug 24; 8(4):e0007323. PubMed ID: 37389412
    [Abstract] [Full Text] [Related]

  • 10. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
    Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV.
    Clin Vaccine Immunol; 2014 Mar 24; 21(3):366-82. PubMed ID: 24403527
    [Abstract] [Full Text] [Related]

  • 11. Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines.
    Kaminski RW, Turbyfill KR, Chao C, Ching WM, Oaks EV.
    Clin Vaccine Immunol; 2009 Apr 24; 16(4):574-86. PubMed ID: 19225079
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mucosal adjuvant properties of the Shigella invasin complex.
    Kaminski RW, Turbyfill KR, Oaks EV.
    Infect Immun; 2006 May 24; 74(5):2856-66. PubMed ID: 16622224
    [Abstract] [Full Text] [Related]

  • 15. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV, Roberts F, Verma NK.
    FEMS Immunol Med Microbiol; 2006 Apr 24; 46(3):444-51. PubMed ID: 16553820
    [Abstract] [Full Text] [Related]

  • 16. From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine's Refinement and Evolution.
    Turbyfill KR, Clarkson KA, Oaks EV, Kaminski RW.
    Vaccines (Basel); 2022 Apr 01; 10(4):. PubMed ID: 35455297
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition.
    Mukhopadhaya A, Mahalanabis D, Khanam J, Chakrabarti MK.
    Vaccine; 2003 Jun 20; 21(21-22):3043-50. PubMed ID: 12798648
    [Abstract] [Full Text] [Related]

  • 19. [Construction and characterization of a live attenuated Shigella flexneri 2a vaccine strain, sf301 Delta virG and dsbA33G].
    Yang XF, Zhou L, Zheng J, Si LS, Wang YL.
    Wei Sheng Wu Xue Bao; 2005 Oct 20; 45(5):748-52. PubMed ID: 16342769
    [Abstract] [Full Text] [Related]

  • 20. Cloning, expression, and affinity purification of recombinant Shigella flexneri invasion plasmid antigens IpaB and IpaC.
    Picking WL, Mertz JA, Marquart ME, Picking WD.
    Protein Expr Purif; 1996 Dec 20; 8(4):401-8. PubMed ID: 8954886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.